Benitec Biopharma Inc.
BNTC
$13.59
-$0.305-2.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -45.42% | -7.18% | -10.31% | 37.06% | -14.18% |
| Total Depreciation and Amortization | -10.99% | 0.00% | 1.11% | 12.50% | -2.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.85% | -4.19% | 136.46% | 104.26% | 3.30% |
| Change in Net Operating Assets | -1,043.40% | -106.01% | 140.63% | -272.44% | 4.57% |
| Cash from Operations | -67.97% | -39.27% | 46.61% | -14.97% | -17.22% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.46% | -49.64% | -- | -100.00% | -99.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -17.47% | -45.96% | -- | -100.00% | -99.86% |
| Foreign Exchange rate Adjustments | 404.30% | -1,760.00% | -104.35% | 170.55% | -462.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.50% | -53.84% | 690.07% | -13.54% | -123.47% |